Abstract

This cross-sectional observational study evaluated the availability and switching patterns of branded generics of Vildagliptin, an antidiabetic medication, in a real-world setting. Data from 967 prescriptions obtained from various pharmacies over a 3-month period post-patent expiration were analyzed. The study revealed a diverse range of branded generics, highlighting challenges in consistent availability. Switching patterns were observed, with a significant proportion of patients deviating from the initially prescribed branded generic. These findings emphasize the need for strategies to improve availability and promote appropriate use of branded generics, enhancing cost-effective diabetes management and patient care. Further research is warranted to investigate factors influencing brand switching behaviors and their impact on patient outcomes. This study provides valuable insights for optimizing the prescribing and availability of branded generics, ultimately enhancing the quality of care for patients requiring Vildagliptin treatment.